Accedi

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.

Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more drugs and are blocked faster than muscles with a lesser blood supply and a smaller blood flow. The drug's actions are terminated when redistributed to other tissues. The duration of action is directly correlated to the elimination half-life. Some drugs like pancuronium, d-tubocurarine, doxacurium and pipecuronium are excreted unchanged in the urine and have a long elimination half-life and duration of action lasting more than 60 minutes. Other drugs like atracurium and cisatracurium undergo spontaneous ester hydrolysis in plasma. Certain amino steroid blockers like vecuronium and rocuronium are metabolized in the liver. Although such metabolites have half the activity of the parent drug, they are usually not formed in amounts required to produce blockade. The drugs metabolized in the plasma or liver have a shorter elimination half-life and action duration lasting only 20 to 40 minutes. Other drugs are also excreted unchanged through the bile.

Tags

Nondepolarizing Neuromuscular BlockersPharmacokineticsIntravenous AdministrationMuscle Blood SupplyDrug RedistributionElimination Half lifePancuroniumD tubocurarineDoxacuriumPipecuroniumAtracuriumCisatracuriumVecuroniumRocuroniumSpontaneous Ester Hydrolysis

Dal capitolo 7:

article

Now Playing

7.5 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

Skeletal Muscle Relaxants

404 Visualizzazioni

article

7.1 : Giunzione Neuromuscolare E Blocco

Skeletal Muscle Relaxants

2.6K Visualizzazioni

article

7.2 : Classificazione dei miorilassanti scheletrici

Skeletal Muscle Relaxants

2.3K Visualizzazioni

article

7.3 : Bloccanti neuromuscolari non depolarizzanti (competitivi): meccanismo d'azione

Skeletal Muscle Relaxants

1.2K Visualizzazioni

article

7.4 : Bloccanti neuromuscolari non depolarizzanti (competitivi): azioni farmacologiche

Skeletal Muscle Relaxants

342 Visualizzazioni

article

7.6 : Bloccanti depolarizzanti: meccanismo d'azione

Skeletal Muscle Relaxants

1.0K Visualizzazioni

article

7.7 : Bloccanti depolarizzanti: Farmacocinetica

Skeletal Muscle Relaxants

277 Visualizzazioni

article

7.8 : Miorilassanti ad azione diretta: Dantrolene e Tossina botulinica

Skeletal Muscle Relaxants

596 Visualizzazioni

article

7.9 : Miorilassanti scheletrici: effetti avversi

Skeletal Muscle Relaxants

306 Visualizzazioni

article

7.10 : Miorilassanti scheletrici: usi terapeutici

Skeletal Muscle Relaxants

432 Visualizzazioni

article

7.11 : Agenti spasmolitici: classificazione chimica

Skeletal Muscle Relaxants

828 Visualizzazioni

article

7.12 : Miorilassanti ad azione periferica e centrale: un confronto

Skeletal Muscle Relaxants

2.9K Visualizzazioni

article

7.13 : Miorilassanti ad azione centrale: usi terapeutici

Skeletal Muscle Relaxants

558 Visualizzazioni

JoVE Logo

Riservatezza

Condizioni di utilizzo

Politiche

Ricerca

Didattica

CHI SIAMO

Copyright © 2025 MyJoVE Corporation. Tutti i diritti riservati